Dr_Microbe One of my favorite duties as the leader of our Seeking Alpha Investing Group is answering questions from members and providing analysis of their prospective trades or tickers. Recently, one of the members inquired about X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) and why the ticker was selling off following they publicized mixed interim data from mavorixafor’s Phase II study for chronic neutropenia (CN). The data revealed that 3 out of 23 patients on Mavorixafor discontinued due to non-serious adv ...